Research · Sep 3, 2026
QGEN Qiagen Thesis 2026: QuantiFERON Latent TB Drives Sample to Insight Molecular Diagnostics Recurring Consumables Growth
QIAGEN N.V. (NYSE: QGEN; FSE: QIA) FY2026 thesis centers on continued QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline (~$1.30-1.50B revenue) + Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline (~$0.70-0.85B revenue) under continued President + CEO Thierry Bernard since March 2020 (~6-year tenure as Qiagen CEO; selected post-March 2020 succession from Peer Schatz departure + selected post-March 2020 succession from Qiagen Molecular Diagnostics business unit head background + selected primary architect of post-2020-2025 ~5 pillars of growth strategy QuantiFERON + QIAstat-Dx + QIAcuity digital PCR + Sample Technologies + QIAGEN Digital Insights + post-2020 ~$10B+ failed Thermo Fisher acquisition rejection). FY2025 revenue ~$2.00-2.20B (+3-8% YoY, ~+5-10% CER) with adj. EPS ~$2.30-2.65. QGEN operates 2 primary segments: Molecular Diagnostics ~63-68% revenue ($1.30-1.50B; QuantiFERON + QIAstat-Dx + NeuMoDx + QIAcuity + companion diagnostics + clinical molecular testing) + Life Sciences ~32-37% revenue ($0.70-0.85B; Sample Technologies + QIAGEN Digital Insights + PCR + assay technologies + genomics + applied testing) with geographic mix Americas ~45-50% + EMEA ~30-35% + Asia Pacific / Rest of World ~20-25% and recurring consumables + reagents revenue mix ~85-90% aggregate. QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline (~$1.30-1.50B revenue + ~63-68% revenue mix): selected primary QuantiFERON-TB Gold Plus (~#1 aggregate global interferon-gamma release assay (IGRA) latent tuberculosis test + ~$0.40-0.50B aggregate QuantiFERON revenue + ~+10-20% aggregate QuantiFERON revenue growth + recurring consumables + CDC + WHO latent TB screening guideline tailwind + replacement of tuberculin skin test (TST)) + QIAstat-Dx syndromic multiplex PCR (respiratory + gastrointestinal + meningitis + ~$0.10-0.20B aggregate QIAstat-Dx revenue + ~+15-30% aggregate growth) + NeuMoDx (high-throughput molecular testing) + QIAcuity digital PCR (~$0.10-0.15B aggregate QIAcuity revenue + ~+15-30% aggregate growth) + companion diagnostics (~25+ aggregate pharma companion diagnostic partnerships + therascreen + liquid biopsy) + ~85-90% aggregate Molecular Diagnostics recurring consumables + reagents revenue mix + ~20-25% aggregate Molecular Diagnostics operating margin. Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline (~$0.70-0.85B revenue + ~32-37% revenue mix; Strategic Catalyst): selected primary Sample Technologies (~#1-2 aggregate global sample preparation / nucleic acid extraction market position + QIAcube + EZ2 + QIAsymphony + ~$0.30-0.40B aggregate Sample Technologies revenue + recurring consumables + reagents) + QIAGEN Digital Insights (bioinformatics + clinical interpretation software + ~$0.10-0.15B aggregate QIAGEN Digital Insights revenue + ~+5-15% aggregate growth + ~AI/ML genomic interpretation) + PCR + assay technologies + genomics + NGS sample prep + ~$0.20-0.30B aggregate PCR + assay + genomics revenue + pharma + academic + applied testing (forensics + food safety + veterinary) end-markets + ~15-20% aggregate Life Sciences operating margin (below Molecular Diagnostics). Capital position + balance sheet: ~$0.00-0.30 aggregate annual dividend (buyback-focused capital return; post-2024 modest dividend initiation considerations) + ~$200-700M aggregate FY2025 buybacks + aggregate capital return ~$200-700M FY2025 + aggregate cash + investments ~$0.6-1.0B + ~$1.0-1.5B aggregate gross debt + ~$0.0-0.5B aggregate net debt + net leverage ~~0-1.5x Net Debt/EBITDA + investment-grade BBB+/Baa1 credit rating + ~215-225M aggregate diluted shares. FY2026 base case ~$2.10-2.35B aggregate revenue + ~$2.55-2.95 adj. EPS + ~$200-750M aggregate capital return; bull case QuantiFERON Latent TB + Molecular Diagnostics Recurring Consumables pipeline acceleration (QuantiFERON ~+10-20% revenue growth + CDC + WHO latent TB screening guideline tailwind + replacement of tuberculin skin test + QIAstat-Dx ~+15-30% revenue growth + QIAcuity ~+15-30% revenue growth + companion diagnostics + ~85-90% recurring consumables mix + ~20-26% Molecular Diagnostics operating margin) + Sample Technologies + QIAGEN Digital Insights + Life Sciences pipeline acceleration (Sample Technologies ~#1-2 global sample prep market position + QIAGEN Digital Insights AI/ML genomic interpretation + instrument placement + consumables pull-through + academic + pharma research funding normalization + ~15-22% Life Sciences operating margin) drives ~$2.25-2.50B aggregate revenue + ~$2.85-3.30 EPS; bear case Roche + Abbott + Hologic + bioMérieux + Cepheid + Thermo Fisher + Danaher + Bio-Rad + Illumina + Revvity (Oxford Immunotec T-SPOT.TB) + DiaSorin competitive intensification + molecular diagnostics + IGRA latent TB + syndromic PCR + digital PCR competitive considerations + clinical lab consolidation considerations + reagent + consumables pricing considerations + CDC + WHO latent TB screening guideline considerations + academic + pharma research funding cycle considerations + NIH budget considerations + China research demand cycle considerations + companion diagnostics partnership considerations + FDA + EU IVDR regulatory considerations + post-March 2020 Thierry Bernard CEO succession planning considerations (~6-year tenure) drives ~$2.00-2.10B revenue + ~$2.20-2.50 EPS.